Rapid-release psychostimulants are commonly used to treat attention-deficit hyperactivity disorder (ADHD), but midday dosing requirements and poor compliance rates have prompted the development of sustained-release formulations. Sustained-release methylphenidate has been shown to have efficacy equal to that of the regular-release formulation and may be preferable when it is difficult or impossible to provide midday doses. Proper management of ADHD includes choosing the proper medication dosage, minimizing side effects of medications and periodically reevaluating the patient's progress.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Diurnal changes in blood pressure and heart rate in children with narcolepsy with cataplexy.
J Sleep Res
April 2023
Division of Sleep Medicine, Peking University People's Hospital, Beijing, China.
The hypocretin neurons in the lateral hypothalamus are connected not only to brain alertness systems but also to brainstem nuclei that regulate blood pressure and heart rate. The premise is that regulation of blood pressure and heart rate is altered and affected by methylphenidate, a stimulant drug in children with narcolepsy with cataplexy. The changes in 24-hr ambulatory systolic and diastolic blood pressure and heart rate were compared among pre-treated narcolepsy with cataplexy patients (40 males, 10 females), with mean age 10.
View Article and Find Full Text PDFTreatment of severe morning sleep inertia with bedtime long-acting bupropion and/or long-acting methylphenidate in a series of 4 patients.
J Clin Sleep Med
April 2021
Hasbro Children's Hospital Sleep Medicine Program, Department of Medicine and Pediatrics, Alpert Medical School of Brown University, Providence, Rhode Island.
Study Objectives: To assess the benefit of bedtime long-acting bupropion and/or long-acting methylphenidate in the therapy of severe morning sleep inertia (SI), a chronic condition that has major adverse consequences on level of functioning and quality of life, and for which there is no recognized therapy.
Methods: Patients underwent clinical interviews and examinations and completed comprehensive questionnaires. They underwent overnight video-polysomnography and next-day multiple sleep latency testing (apart from 1 case with obstructive sleep apnea).
[Treatment of attention-deficit/hyperactivity disorder in clinical practice. A retrospective study].
Medicina (B Aires)
March 2020
Laboratorio de Neurociencias (IUNICS), Son Ferriol, Islas Baleares, España. E-mail:
Attention deficit hyperactivity disorder (ADHD) is a complex and heterogeneous neurodevelopmental disorder, of a chronic nature, of multifactorial etiology, mainly due to genetic and environmental factors. We conducted a retrospective analytical study of the t herapeutic management of children diagnosed with ADHD. A sample of 82 children diagnosed with ADHD (74.
View Article and Find Full Text PDFMethylphenidate disintegration from oral formulations for intravenous use by experienced substance users.
Drug Alcohol Depend
September 2017
Mental Health Services, Landspitali - The National University Hospital, 101 Reykjavik, Iceland; Faculty of Medicine, Department of Psychiatry, University of Iceland, 101 Reykjavík, Iceland.
Background And Aims: Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder. MPH is currently the preferred substance among most intravenous (i.v.
View Article and Find Full Text PDFNew Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
CNS Drugs
February 2017
Division of Child and Adolescent Neuropsychiatry, University of Turin, Piazza Polonia 94, 10126, Turin, Italy.
Psychostimulants are the recommended first-line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate is one of the most commonly used psychostimulants worldwide. Given that immediate-release and/or tablet/capsule formulations may decrease adherence to methylphenidate treatment, several drug companies have been developing novel long-acting and/or liquid/chewable formulations that may improve adherence as well as (for long-acting formulations) reduce abuse potential, decrease stigma associated with multiple administrations per day, and decrease the potential for adverse effects related to dosage peak.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!